Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have histologically confirmed and newly diagnosed operable breast cancer~* HER2 positive (all FISH +)~* Axillary node positive (by PET or cytologically determine node by sonography) and/or tumor size \> 5 cm -No prior hormonal, chemotherapy or radiotherapy is allowed.~* No breast operation other than biopsy to make diagnosis is allowed.~* Age: 18-years and older, not pregnant pre-, and postmenopausal women with good performance status (ECOG 0-1)~* Adequate hematopoietic function:~Absolute granulocyte count ³1500/mm3,~* platelet ³100,000/mm3, Hemoglobin ³ 10 g/mm3~* Adequate renal function: Serum creatinine £ 1.5 mg/dl~* Adequate hepatic function: total bilirubin: £ 1.5 mg/dl, AST/ALT: £ 2 times normal, Alkaline phosphatase: £ 2 times normal-Adequate cardiac function:~  1. normal or nonspecific EKG taken within 1 mo of enrollment~ 2. LVEF ³ 50% by MUGA or Echocardiogram taken within 1 mo of enrollment~* Normal mental function to understand and sign the consent~Exclusion Criteria:~* patients who received hormonal, chemotherapy or radiotherapy for breast cancer~* patients who underwent surgery for breast cancer~* patients with a history of uncompensated congestive heart failure~* Patients with node-negative stage IIA (T2N0) breast cancer~* Patients who have history of cancer other than in situ uterine cervix cancer or nonmelanotic skin cancer

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Paclitaxel/Gemcitabine/Trastuzumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).